# Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

> **NCT00000809** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections
- HIV Seronegativity

## Interventions

- **BIOLOGICAL:** Aluminum hydroxide
- **BIOLOGICAL:** QS-21
- **BIOLOGICAL:** MN rsgp120/HIV-1

## Key facts

- **NCT ID:** NCT00000809
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000809, "Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00000809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*